![[exit]](/exit-outline.svg "Leave")
![[3D]](/images/icons/circle-nodes-solid.svg "Visit 3D graph view for this node"){kind=icon}
RapastinelB
Pharmacology 
Rapastinel (former developmental code name GLYX-13) is a novel antidepressant peptide whose mechanism is modulating NMDA. It seems reliant on NR2B [1] for its antidepressant effect.
Rapastinel has been superseded with improved compounds such as Apimostinel (Analog), and Zelquistinel (Small Molecule). Compared to the sucessors, Rapastinel has worse pharmacokinetics, and lacks stability. Compared to Apimostinel, it is 1000-fold less potent.
The half-life of rapastinel is short, below 30 minutes, however the effects last for a week [NEEDS REF].
Sources
[ 1 ] Commentary: GLYX-13 Ameliorates Schizophrenia-Like Phenotype Induced by MK-801 in Mice: Role of Hippocampal NR2B and DISC1